CVRx (CVRX) Set to Announce Earnings on Tuesday

CVRx (NASDAQ:CVRX) is scheduled to release its earnings data after the market closes on Tuesday, October 29th. Analysts expect CVRx to post earnings of ($0.45) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings data on Monday, July 29th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). The company had revenue of $11.81 million for the quarter, compared to analysts’ expectations of $11.84 million. CVRx had a negative return on equity of 77.62% and a negative net margin of 122.52%. During the same quarter last year, the business posted ($0.56) EPS. On average, analysts expect CVRx to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Stock Down 0.4 %

CVRX opened at $10.07 on Monday. CVRx has a twelve month low of $6.40 and a twelve month high of $33.13. The company’s 50-day moving average price is $8.77 and its two-hundred day moving average price is $9.65. The stock has a market cap of $217.47 million, a price-to-earnings ratio of -4.08 and a beta of 1.26. The company has a quick ratio of 8.85, a current ratio of 10.08 and a debt-to-equity ratio of 0.53.

Insider Activity at CVRx

In related news, CEO Kevin Hykes bought 30,000 shares of the business’s stock in a transaction on Monday, August 5th. The stock was acquired at an average price of $8.36 per share, for a total transaction of $250,800.00. Following the purchase, the chief executive officer now directly owns 30,000 shares in the company, valued at $250,800. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have purchased 38,500 shares of company stock worth $322,545. 18.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Canaccord Genuity Group upped their price objective on CVRx from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, July 30th. Lake Street Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of CVRx in a research report on Monday, August 26th. Craig Hallum decreased their price objective on CVRx from $23.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, July 11th. Piper Sandler dropped their price objective on shares of CVRx from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Tuesday, July 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $14.00 target price on shares of CVRx in a research report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.67.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.